anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The life expectancy of persons infected with HIV has improved greatly since the institution of combination antiretroviral therapy (cART). However, many metabolic derangements have been discovered with long-term cART therapy, including lipodystrophy, insulin resistance, and, more recently, abnormal bone metabolism. It is well documented that bone mineral density (BMD) in HIV+ patients is lower when compared with the expected BMD in non-HIV patients \[1-10\]. The underlying cause of lower BMD is unknown but it is felt to be a multifactorial process \[10-14\]. Current guidelines recommend first line treatments consist of a combination of protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). Despite the known change in BMD in HIV+ persons, less is known about the effect of antiretroviral (ART) exposure and duration of treatment, ART type, and cumulative HIV viremia on bone health. This is demonstrated by studies showing loss of BMD with use of protease inhibitors compared to other regimen \[15\], other studies showing more detrimental effect from NRTIs \[6, 9, 16\], and yet others that have shown that BMD improves with all ART therapy \[17\]. Tenofovir (an NRTI), in particular, has been implicated as playing a role in bone changes, possibly due to its effect at the proximal tubule leading to a Fanconi-like syndrome with phosphate wasting \[18\]. Tenofovir led to significant reductions in BMD of children and this loss reversed after tenofovir was stopped \[9\]; other studies have shown similar deleterious effects \[16\]. A recent study evaluating the effect of continuous ART therapy vs. intermittent use for viral suppression showed that patients receiving continuous ART had greater loss of BMD, despite an increased risk of AIDS progression, myocardial infarction, or renal- or liver-failure \[19\]. However, prior longitudinal studies with longer follow-up have shown that the initial loss of BMD following ART is recovered and longer-term BMD changes are similar to changes seen in HIV-negative persons \[20-22\]. There is evidence that there is a positive correlation between HIV viremia and proinflammatory cytokines and that up-regulated proinflammatory cytokines may play a role in both osteoclast and osteoblast function. Prior studies have shown that during HIV infection osteoblast and osteoclast function is uncoupled and following ART treatment, regulation of bone turnover and formation ensues \[23\]. However, changes in cytokines have not been correlated with BMD and changes in bone turnover during routine ART treatment, to our knowledge. Most studies to date have been cross-sectional studies comparing HIV+ (with varying ART exposure histories) and HIV- persons or small longitudinal studies with limited sample sizes and short duration. It is not known if the decline of proinflammatory cytokines which occurs concurrent with the fall in HIV viral loads leads to improved regulation of bone formation and hence a lower rate of bone loss and lower risk of fracture.
The study was conducted on 30 volunteers who met the inclusion criteria among female students studying at Haliç University Faculty of Health Sciences. The "Premenstrual Syndrome Scale (PMSS)" was used to assess the individuals' premenstrual symptoms; the "Visual Analog Scale (VAS)" was used to assess pain for each of the abdominal, lumbar and general body pain; and the "Pittsburgh Sleep Quality Index (PSQI)" was used to assess sleep quality. Then, the participants were randomly divided into two groups as "Group 1: Control group (n=15)" and "Group 2: - Calisthenic home exercise group (n=15)". Participants in the first group were not subjected to any intervention and were asked not to participate in any exercise program for eight weeks. Participants in the second group were informed about calisthenic home exercise programs face to face and were asked to perform these exercises as home exercises for eight weeks. At the end of the treatment process, participants' PMSS, VAS and PSQI scores were re-evaluated.Statistical analysis will be performed with SPSS 24.0 program. If the data is parametric, paired sample t-test will be used for within-group evaluation; independent sample t-test will be used for between-group evaluation. If the data is non-parametric, Wilson test will be used for within-group evaluation and Mann Whitney U test will be used for between-group evaluation.
PURPOSE:To surface-treat superfine grains in one step in a gas phase by mixing a surface-reforming volatile metallic compd. into the metal oxide superfine grains formed by a gas phase method and used as nuclei and treating the mixture in a gas phase. CONSTITUTION:(a) A volatile metallic compd. (e.g. titanium tetra-isopropoxide) is gasified or atomized with (b) a carrier gas (e.g. gaseous nitrogen), mixed with steam at <=600 deg.C and hydrolyzed or heated above the decomposition temp. and pyrolyzed to form the metal oxide superfine grains (A) having 0.005-0.1mum average diameter and 0.001-0.5mum grain diameter distribution and used as the nuclei. After the A component is formed, (D) a surface-reforming volatile metallic compd. (e.g. aluminum tri-secondarybutoxide) having a concn. lower than that of the A component is immediately mixed so that the ratio of the A component flow velocity u1 to the B component flow velocity u2 is controlled to >=0.1, and the mixture is treated in a gas phase to reform the surface of the A component with the B component.
The present invention relates to a medical apparatus ( 901, 100 ) for assisting clinicians, nurses or other users in choosing an intervention for the treatment of a patent suffering from an acute dynamic disease, e.g. sepsis. The medical apparatus is based on a method where a model of the disease is adapted or personalised to the patient. To ensure that the apparatus remains capable of predicting the health of the patient, the apparatus is continuously-provided with new patient values and the model is continuously adapted to the new patient values. Since the medical apparatus is configured to be continuously adapted to current state of health, the apparatus is able to assist the user by generating disease management information, e.g. suggestions for medications, to an output device ( 902, 104 ).
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use, excellent in preventing and reducing effects on pigmentation in skin such as blackening, dermal stains or ephelides of the skin after sunburn and having high safety by including an extract from a specific crude drug plant having suppressing action on the melanogenesis as an active ingredient therein. SOLUTION: This skin preparation for external use comprises an extract from Cancer ccora which is a crude drug plant produced in Peru of South America. Stachys bogotensis is especially preferred as the Cancer ccora. The resultant extract is preferably extracted with a polar solvent. The content of the extract is 0.001-20wt.%, based on the total amount of the skin preparation for external use and expressed in terms of dry solids. A dosage form such as a cream, a milky lotion or an oil is preferred as the skin preparation for external use.
Over the last thirty years, substantial evidence has accumulated in support of the hypothesis that dysregulation of inflammatory processes plays a critical role in the pathophysiology of depression. This review traces the evolution of research supporting this link, discussing key findings from several major investigative fronts: Alterations in inflammatory markers associated with depression; Mood changes following the exogenous administration of inflammatory challenges; The anti-inflammatory properties of traditional antidepressants and the promising antidepressant effects of anti-inflammatory drugs. Additionally, it explores how inflammatory processes interact with specific brain regions and neurochemical systems to drive depressive pathology. A thorough analysis of the 100 most-cited experimental studies on the topic ensures a comprehensive, transparent and unbiased collection of references. This methodological approach offers a panoramic view of the inflammation-depression nexus, shedding light on the complexity of its mechanisms and their connections to psychiatric categorizations, symptoms, demographics, and life events. Synthesizing insights from this extensive research, the review presents an integrative model of the biological foundations of inflammation-associated depression. It posits that we have reached a critical juncture where the translation of this knowledge into personalized immunomodulatory treatments for depression is not just possible, but imperative.
OBJECTIVE: The aim of this study was to investigate the effects of uterine massage performed before placental delivery on the third stage of labor and postpartum hemorrhage after vaginal delivery.
MATERIALS AND METHODS: The study was designed as a prospective randomized controlled study. Between June 2018 and June 2019, 242 women who gave birth in Istanbul Kanuni Sultan Suleyman Training and Research Hospital were included in the study. The women were divided into two groups; group 1 received uterine massage after vaginal delivery before placental delivery (n: 128) and group 2 did not receive massage (n: 114). Demographic characteristics, delivery times of the baby and placenta, duration of uterine massage, amount of postpartum hemorrhage and postpartum hemoglobin values of both groups were recorded.
RESULTS: Baseline characteristics were similar in both groups. Placental output time after delivery was 8.3 ± 4.2 min in group 1 and 13.5 ± 6.3 min in group 2. The third stage of labor was significantly shorter in group 1 (p = 0.012). The amount of blood loss of 500 mL or more after delivery was higher in group 2 but not statistically different (p > 0.05). Hemoglobin value measured within 12-24 h after delivery was significantly lower in group 2 (hemoglobin < 8 g/dL after 12-24 h p = 0.003; hemoglobin < 10 g/dL after 12-24 h p = 0.001). Delta hb value was also significantly lower in group 2 (p = 0.03). With this result, it was determined that bleeding intense enough to require transfusion was more common in group 2.
CONCLUSION: In patients delivering vaginally, uterine massage before placental delivery shortens the placental delivery time and reduces postpartum hemorrhage. In addition to oxytocin and controlled cord traction to reduce postpartum blood loss, uterine massage should be routinely used in the active management of the third stage of labor.
CLINICAL TRIALS NUMBER: NCT03858569.
Participants will be randomized to receive NNC0638-0355. The study will be conducted in 4 parts. Part A: Single ascending dose (SAD) Part B, C and D: Multiple ascending dose (MAD).
Patients in the usual care group will receive care as dictated by their clinical team. In usual care in the study institution, patients frequently receive medication reconciliation by and ICU pharmacist at the time of transfer out of the ICU to the hospital ward, medication reconciliation by a physician at the time of hospital discharge, and follow up with their primary care physician within two weeks of hospital discharge. Usual care does not currently include an in-person assessment of the patient's cognitive and functional status or anticipated post-ICU needs by a nurse practitioner between ICU transfer and hospital discharge, access to a 24/7 contact line after hospital discharge, or assessment in a multi-disciplinary ICU Recovery Clinic.
In clinical trials the efficacy of fondaparinux sodium in the elderly (65 years or older) was similar to that seen in patients younger than 65 years; however, serious adverse events increased with age. When using fondaparinux sodium in elderly patients, paying particular attention to dosing directions and concomitant medications (especially anti-platelet medication). [see Warnings and Precautions (5.2)] 

Fondaparinux sodium is substantially excreted by the kidney, and the risk of adverse reactions to fondaparinux sodium may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, assess renal function prior to fondaparinux sodium administration. [see Contraindications (4), Warnings and Precautions (5.3), and Clinical Pharmacology (12.4)] 

In the peri-operative hip fracture, hip replacement, or knee replacement surgery clinical trials with patients receiving fondaparinux sodium 2.5 mg, serious adverse events increased with age for patients receiving fondaparinux sodium. The incidence of major bleeding in clinical trials of fondaparinux sodium by age is provided in Table 6.

Table 6. Incidence of Major Bleeding in Patients Treated With Fondaparinux Sodium by Age

a Includes hip fracture, hip replacement, and knee replacement surgery prophylaxis.
Thoracotomy is among the most painful surgical procedures and can cause severe pain. This pain causes postoperative complications in patients who have thoracotomy surgery. Uncontrolled pain can cause respiratory and thromboembolic events. Therefore, effective pain management is important in patients undergoing thoracotomy. Investigators aim to compare the analgesic effectiveness and complications of thoracic paravertebral block and serratus anterior plane block in relieving thoracotomy pain, which is one of the most painful surgical procedures. It is aimed to compare the effectiveness and complications of thoracic paravertebral block and serratus plane block in postoperative pain control after thoracotomy. Providing pain control reduces postoperative complications and reduces hospital stay, which increases patient comfort and reduces costs. In this research, postoperative morphine consumption after block applications will be compared, and patients' analgesic needs will be evaluated according to the participants' VAS score. Post-operative 3rd, 6th, 9th, 12th, 24th. Morphine consumption will be evaluated by monitoring the hours. It will be evaluated whether there is a need for additional analgesics. During the operation, the patient's heart rate, blood pressure, saturation and temperature variable values will be closely monitored. Standard monitoring methods will be used when examining these parameters.
The safety and effectiveness of foscarnet sodium injection in pediatric patients have not been established. Foscarnet sodium is deposited in teeth and bone and deposition is greater in young and growing animals. Foscarnet sodium has been demonstrated to adversely affect development of tooth enamel in mice and rats. The effects of this deposition on skeletal development have not been studied.

Since deposition in human bone has also been shown to occur, it is likely that it does so to a greater degree in developing bone in pediatric patients. Administration to pediatric patients should be undertaken only after careful evaluation and only if the potential benefits for treatment outweigh the risks.
Oxaliplatin 25 mg/m\^2 IV per day MTD on days 1-4 before Fludarabine. Fludarabine 30 mg/m\^2 daily IV over 30 minutes on days 2-4. Cytarabine 500 mg/m\^2 daily IV, 2-hour infusion starting 4 hours after fludarabine dose started, on days 2-4. Rituximab 375 mg/m\^2 IV on day 3, course 1 (on day 1, subsequent courses). Pegfilgrastim 6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy.
Participants receiving "Usual Care" group (A), will be recruited during the last two months of treatment (T-2). At the end of treatment (T0), participants will complete a knowledge questionnaire and will be followed for another 24 months. At six months after treatment completion (T6), a final follow-up knowledge assessment will be conducted. Participants will be enrolled into group A until the intended sample size of 50 participants is reached. Investigators estimated to have reached this number within four to six months based on recent survival rates.
Different doses of oral pazopanib once daily for the duration of the study starting on Day 1 of Treatment Period 1. Treatment continues until disease progression or withdrawl from study.
The labrum is a structure which provides stability to the shoulder joint. A superior labral tear from anterior to posterior lesion is an injury to the labrum at the insertion of the biceps muscle. The grading system is related to the severity of the tear. A type 2 tear is an intermediate grade tear. These are commonly treated in two ways: either by repairing the labrum with bone anchors or by cutting the biceps tendon and re-affixing it more distally. No method has been shown to be superior to the other and surgeons generally choose to proceed however they are most comfortable. The study will seek to determine how these injuries are best treated. Inclusion criteria: patients with type 2 superior labral tear from anterior to posterior tears who are under the age of 45. Throwing athletes are excluded due to their unique demands.

Subjects will be randomly assigned to one of two groups. Prior to surgery patients will be evaluated in clinic, full histories and physicals will be performed and their functional status will be evaluated using validated questionnaires including the American Shoulder and Elbow Society score and quality of life measurements.

Both groups will be treated first with a shoulder arthroscopy. The experimental portion of the study will involve whether the patient is then treated with repair of the Superior Labrum Anterior and Posterior lesion or with tenodesis. Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum. A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm. Physical therapy will be initiated after surgery and will be identical in both groups. It will be recommended but not required as part of the study. Progress notes, operative reports, and questionnaires will also be retained as part of the study. Patients will be in a sling for the first 4 weeks after surgery. Post-operatively, physical examinations findings and American Shoulder and Elbow Surgeons scores at 3, 6, and 12 months. These will be compared to the preoperative results and to the other experimental arm of the study. Post-operative imaging will not be obtained. No computerized tomographies will be required as part of the study. No Magnetic Resonance Imagings will be required as part of the study--patients enrolled in the study will likely have had an MRI performed outside of the study period to determine if they have an isolated Superior Labrum Anterior and Posterior tear but no MRIs will be performed as part of the study. No lab reports or Physical therapy reports will be included in the study.
FIELD: medicine, endocrinology. SUBSTANCE: invention relates to treatment of non-insulin dependent diabetes mellitus (type II). Method of treatment involves administration of pharmaceutical composition comprising essentially or involving synthetic chrome tripicolinate in the dose from 1 000 to 10 000 mcg that is equal to daily curative dose of preparation. Invention provides the enhanced effectiveness of diabetes mellitus treatment using chrome compound. EFFECT: improved method of treatment. 28 cl, 1 ex
The invention relates to the field of pharmaceutical chemistry and medicine. It refers to a new water-soluble antiviral agent based on silver-cistine compound of the formula C6H19N4O6S2LiAg2 and to the method of preparing thereof. The claimed agent may be prepared at room temperature by mixing the following components: cistine, lithium hydroxide, silver nitrate and ammonia taken in a molar ratio of 1 :2:2:8. The reaction mixture is kept at room temperature for 6 hours, and then evaporated in vacuum up to 1/4 of the initial volume at a temperature of 40-50°C. To the obtained suspension an equivalent amount of ethanol is added, the mixture is cooled up to +4 - +6°C and held for 12 hours. The obtained target product in the form of yellow fine precipitate is filtered, washed with ethanol and dried in vacuum at room temperature.
Achalasia is characterized by incomplete or absent relaxation of the lower esophageal sphincter (LES) and loss of esophageal peristalsis which leads to dysphagia. Standard of care for achalasia includes endoscopic management (dilation and injection of injection of botulinum toxin) and surgery, however both of these options carry procedural risks, may lose efficacy over time and many patients are not appropriate candidates for these treatment options. Unfortunately, there are limited oral medications for patients with achalasia. Mirabegron is an oral beta-3 agonist currently FDA approved for overactive bladder that works by relaxing the bladder muscles. Beta-3 receptors have also been identified in the LES with stimulation leading to LES relaxation in preclinical studies. Through a proof of concept pilot study, the investigators aim to evaluate the effect of mirabegron in patients with achalasia via high resolution manometry and a validated dysphagia scale.
Expression of TROP-2, an approximately 35 kDa transmembrane protein and a substrate of protein kinase C, has been linked to several cancers. TROP-2 is also known as GA733-1, epithelial glycoprotein 1 (EGP-I) and tumor-associated calcium signal transducer-2. A monoclonal antibody against TROP-2 from the hybridoma AR47A6.4.2, deposited with the International Depository Authority of Canada (IDAC) as accession number 141205-05, was previously shown to be a cancerous disease modifying antibody (CDMAB), preventing tumour growth and reducing tumour burden in several cancer models including prostate, pancreatic and breast cancer by cytotoxicity. The variable regions of this monoclonal antibody were also isolated, sequenced and complementarity determining regions (CDRs) determined. Now, a chimeric antibody and humanized antibodies are generated that have similar TROP-2 binding activity as the parent 141205-05 monoclonal antibody. The monoclonal, chimeric and humanized antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells to treat cancer. These antibodies are also used in binding assays to determine TROP-2 expression on cells.
The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve damage. Since nt-bAP can cross the blood-brain barrier (BBB), the concentration in the central nervous system and in the periphery are in equilibrium. By sequestering nt-bAP, our device will act as a 'sink.' It should draw nt-bAP across the BBB, reducing the concentration of soluble nt- bAP in the brain, thereby halting or slowing plaque deposition in the brain. Since plaques and possibly soluble, aggregated nt-bAP are the cause of nerve damage in AD, this process should be therapeutically effective. The device can be a depot containing a fragment of nt-bAP which intrinsically retains the ability to bind but not to be toxic.
The present invention relates to a medicament (tinea treating medicament) for treating skin diseases. The medicament shows the effects on tinea corporis and cruris, tinea of feet and hands, acne, neurodermatitis, viral herpes, scrotal damp itch and chigger bite, has the functions for alleviating itch and removing odor, and effectively kills bacteria, fungi, viruses and brood cells. With the protection action of polymer materials, the medicament has no toxicity or harm or corrosion and little irrigation to skin. The medicament is suitable for women and children to use and also suitable for being used on skin at sensitive part. When applied to the skin, the medicament can form a medical film and has the advantages of quick effect taking and long effect lasting. The medicament is mainly prepared from PVP-I, acetylsalicylic acid, oxybenzoic acid, peppermint camphor and macromolecular carrier material.